trikafta launch underway data increas
total cf sale million split estim million street
consensu million driven increas global symdeko/symkevi adopt
forma dilut ep beat street estim trikafta
approv last week physician alreadi prescrib although suppli like
limit due earli approval/launch trikafta provid next leg growth particularli
het/min patient elig therapi also last week vertex
nh england reach licens agreement provid uk cf patient access therapi
forecast cf sale billion year grow billion
look partner crispr crsp report phase data beta
thalassemia sickl cell diseas reiter overweight rate
increas price target
trikafta growth total cf sale million symdeko/
symkevi sale grew sequenti million driven continu global uptak
expans younger patient cannib orkambi fell
million last week fda approv trikafta elexacaftor/ivacaftor/tezacaftor treat
cf patient age homozyg heterozyg mutat
annual wac anticip gross-to-net discount in-lin
vertex therapi expect rapid uptak het/min patient given trikafta
drug approv popul along use homozyg patient
respond well orkambi and/or symdeko physician alreadi
begun prescrib trikafta although suppli like limit due earli approv
vertex file europ remain highli confid european approv
next year forecast trikafta launch drive total cf sale billion
year billion billion
increas price forma dilut ep beat
street estim estim pro forma dilut ep
vertex end cash billion
yet close semma acquisit cash million increas
price target appli multipl pro forma dilut ep
roll forward discount period
data partner crispr report first-ev safeti efficaci
data beta thal scd like decemb last updat beta thal
patient transfus independ month sinc engraft
like one scd patient treat enrol continu
bet thal scd site canada europ
cf drug may fail clinic gain approv may meet expect
vertex biopharmaceut compani develop innov drug
price close octob
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
good sold
thousand except per share data
compani report piper jaffray co analysi
current disclosur inform compani found
